Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) traded up 6.6% on Friday . The stock traded as high as $12.60 and last traded at $12.60. 44,962 shares traded hands during trading, a decline of 38% from the average session volume of 72,367 shares. The stock had previously closed at $11.82.
Gyre Therapeutics Trading Up 5.8 %
The company’s fifty day moving average price is $12.71 and its 200-day moving average price is $14.33.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $25.23 million during the quarter. Sell-side analysts forecast that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.
Insider Transactions at Gyre Therapeutics
Institutional Investors Weigh In On Gyre Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in GYRE. WINTON GROUP Ltd purchased a new position in shares of Gyre Therapeutics in the 2nd quarter valued at about $220,000. Bank of New York Mellon Corp purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $218,000. Renaissance Technologies LLC purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $123,000. Institutional investors and hedge funds own 23.99% of the company’s stock.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- What Are the FAANG Stocks and Are They Good Investments?
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.